GSK (GSK) stock slips as FDA advisors vote against the approval of a combination regimen involving thecompany's blood cancer drug Blenrep. Read more here.

GSK Plc’s blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting its approval in doubt.

The U.S. Food and Drug Administration's panel of independent advisers voted on Thursday against approval of GSK's blood ...

Britain launched a life sciences sector plan on Wednesday to a mixed response from the pharmaceutical industry, which welcomed proposals to boost R&D but warned it would fail to keep firms competitive ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

Glaxosmithkline, with multiple operations in Montco, just scored a major regulatory win that could reshape how lupus ...

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline ...